Human vascular adhesion protein-1 (VAP-1) is a homodimeric 170-kDa sialoglycoprotein that is expressed on the surface of endothelial cells and functions as a semicarbazidesensitiveamineoxidase and as an adhesion molecule. Blockade of VAP-1has been shown to reduce leukocyte adhesion and transmigration in in vivo and in vitro models, suggesting that VAP-1 is a potential target for anti-inflammatory therapy. In this study we have constructed mouse-human chimeric antibodies by genetic engineering in order to circumvent the potential problems involved in using murine antibodies in man. Our chimeric anti-VAP-1 antibodies, which were designed to lack Fc-dependent effector functions, bound specifically to cell surface-expressed recombinant human VAP-1 and recognized VAP-1 in different cell types in tonsil. Furthermore, the chimeric antibodies prevented leukocyte adhesion and transmigration in vitro and in vivo. Hence, these chimeric antibodies have the potential to be used as a new anti-inflammatory therapy.

No abstract

Merge conflicts are common especially in large and distributed software projects. There have been development to both make the conflicts less frequent by introducing better merge algorithms and to aid the user in resolving conflicts by better visualization and other means. However, one element lacking from the current conflict-resolving tools is the utilization of collective knowledge of project members, achievable through web-based collaboration. The person encountering the conflict may not have all the necessary information and understanding for resolving the conflict, in which case it would be beneficial to do the resolving collaboratively by all the parties who have been involved in causing the conflict or who otherwise have valuable information about the conflicted part of the project. In this paper, we present a process for real-time collaborative merging as well as a web-based tool supporting the process. Index Terms-real-time collaboration, version control 4 http://cored.cs.tut.fi

No abstract